Cell line · CVCL_GR23
Papers87
1 to 20 of 87
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial transfer between breast cancer cells promotes ROS-dependent proliferation. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. | Nat Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-Intrinsic Protein Neddylation Modulates the Intratumoral Immune Landscape to Constrain Immune Checkpoint Blockade Therapy. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Linking tumor viability and immune infiltration with dual-nucleus MRI in preclinical models. | Npj Imaging | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synthetic inducible bacteria normalize the microenvironment of refractory tumors, potentiating checkpoint inhibitor responses. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis. | Cancer Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hierarchical Targeting of TREM2+ Myeloid Cells via Acid-Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone-Metastatic TNBC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Detachment-Induced FAK-STAT3-NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Large adipocytes increase vesicle-mediated lipid release and promote breast cancer malignancy. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An AIB1 isoform rewires glucocorticoid receptor signaling to promote TNBC progression. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_GR23/papers